CLINICAL TRIAL

Psilocybin-assisted Cognitive Behavioral Therapy for Depression

The primary objectives of this clinical investigation are to (1) determine the acceptability and feasibility of joining psilocybin-assisted therapy with cognitive-behavioral therapy (PA-CBT) for patients with depression, (2) optimize CBT to most effectively integrate the psilocybin experience with psychotherapy and (3) examine the clinical benefit of psilocybin as an adjunct to cognitive-behavioral therapy (CBT) for major depressive disorder. This study will involve an open trial of PA-CBT where participants will receive two doses of psilocybin (10mg and then 25mg, separated by one month) plus 12 sessions of cognitive behavioral therapy.

Open source BibTeX RIS

Bibliographic context

Journal: ClinicalTrials.gov
Date: 2026-05-18
Source: ClinicalTrials.gov
DOI: Unavailable
PubMed: Unavailable

Authors

University of California Los Angeles

Watch author

Topics and keywords

psilocybin Depression Other Major Depressive Disorder Psilocybin Cognitive behavioral therapy COMPLETED

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Group Psilocybin-assisted Cognitive Behavioral Therapy for Major Depressive DisorderClinicalTrials.gov · 2026-05-03 Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression (EPIsoDE): 6- and 12-Month Naturalistic Follow-Up of a Phase 2b TrialPsychotherapy and Psychosomatics · 2026-05-26 Contribution of the Serotonin 5-HT2A Receptor to the Therapeutic Effect of Psilocin on Social Behavior Deficits in Mice Repeatedly Exposed to Social Defeat StressNeuropsychopharmacology Reports · 2026-08-31 Trajectories of psychedelic-assisted change: An observational study of a psilocybin retreat program followed by psychotherapeutic interventionsJournal of Psychedelic Studies · 2026-07-02 Psilocybin reduces fear memory and restores neuroplasticity in the hippocampus and medial prefrontal cortex.Journal of Psychopharmacology · 2026-06-27 Blocking 5-HT2B receptors abolishes psilocybin’s efficacy in the rat forced swim testJournal of Psychopharmacology · 2026-06-22 Psilocybin-assisted therapy in treatment-resistant depression: rapid remission, uncertain durability, and the next phase of clinical evidenceAnnals of Medicine and Surgery · 2026-06-17 Psilocybin and Mental Health Outcomes: Scoping Review with ☸SAIMSARASAIMSARA Journal · 2026-06-14